Insider Buying: enVVeno Medical Corporation (NASDAQ:NVNO) Director Acquires 9,620 Shares of Stock

enVVeno Medical Corporation (NASDAQ:NVNO) Director Matthew Jenusaitis purchased 9,620 shares of the stock in a transaction dated Thursday, December 19th. The shares were purchased at an average price of $2.53 per share, with a total value of $24,338.60. Following the completion of the transaction, the director now owns 16,545 shares of the company’s stock, valued at approximately $41,858.85. This trade represents a 138.92 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

enVVeno Medical Stock Performance

Shares of enVVeno Medical stock opened at $2.49 on Monday. The business has a 50-day simple moving average of $3.22 and a 200-day simple moving average of $4.36. The company has a market cap of $43.66 million, a PE ratio of -1.93 and a beta of 1.22. enVVeno Medical Corporation has a one year low of $2.45 and a one year high of $6.97.

enVVeno Medical (NASDAQ:NVNO) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.02). On average, sell-side analysts predict that enVVeno Medical Corporation will post -1.3 earnings per share for the current fiscal year.

Institutional Trading of enVVeno Medical

Several institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC lifted its holdings in shares of enVVeno Medical by 7.8% in the 3rd quarter. Geode Capital Management LLC now owns 150,676 shares of the company’s stock valued at $506,000 after buying an additional 10,902 shares during the period. Westside Investment Management Inc. lifted its position in shares of enVVeno Medical by 128.0% during the 3rd quarter. Westside Investment Management Inc. now owns 88,375 shares of the company’s stock valued at $297,000 after acquiring an additional 49,613 shares during the period. Hohimer Wealth Management LLC purchased a new stake in shares of enVVeno Medical during the 3rd quarter worth approximately $286,000. Maven Securities LTD acquired a new position in enVVeno Medical during the third quarter worth $295,000. Finally, Corsair Capital Management L.P. acquired a new position in shares of enVVeno Medical during the 3rd quarter worth $390,000. Hedge funds and other institutional investors own 34.71% of the company’s stock.

enVVeno Medical Company Profile

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).